Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | Director · PRESIDENT AND CEO | October 06, 2026 | October 08, 2026 |
| QUEST DIAGNOSTICS INCDGX · Entity 2118 | Director | May 25, 2021 | May 25, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HALOZYME THERAPEUTICS, INC.
Report date October 06, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 767,780 |
Ending reported balance
After 2026-10-08 transaction · row 15
15 source rows · reconciled sequenceRow 1 · 2026-10-06 · Exercise / conversion · Acquired 20,000 · Balance 787,780 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. Row 2 · 2026-10-06 · Sale · Disposed 2,300 · Balance 785,480 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F2: Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.480 to $108.290. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 3 · 2026-10-06 · Sale · Disposed 6,000 · Balance 779,480 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F3: Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.530 to $109.520. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 4 · 2026-10-06 · Sale · Disposed 9,920 · Balance 769,560 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F4: Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.530 to $110.510. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 5 · 2026-10-06 · Sale · Disposed 1,780 · Balance 767,780 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F5: Represents a weighted average sales price per share. The shares were sold at prices ranging from $110.530 to $111.210. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 6 · 2026-10-07 · Exercise / conversion · Acquired 20,000 · Balance 787,780 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. Row 7 · 2026-10-07 · Sale · Disposed 8,600 · Balance 779,180 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F6: Represents a weighted average sales price per share. The shares were sold at prices ranging from $110.360 to $111.350. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 8 · 2026-10-07 · Sale · Disposed 10,300 · Balance 768,880 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F7: Represents a weighted average sales price per share. The shares were sold at prices ranging from $111.380 to $112.360. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 9 · 2026-10-07 · Sale · Disposed 900 · Balance 767,980 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F8: Represents a weighted average sales price per share. The shares were sold at prices ranging from $112.400 to $113.190. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 10 · 2026-10-07 · Sale · Disposed 200 · Balance 767,780 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F9: Represents a weighted average sales price per share. The shares were sold at prices ranging from $113.590 to $113.860. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 11 · 2026-10-08 · Exercise / conversion · Acquired 20,000 · Balance 787,780 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. Row 12 · 2026-10-08 · Sale · Disposed 4,810 · Balance 782,970 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F10: Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.480 to $108.475. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 13 · 2026-10-08 · Sale · Disposed 3,090 · Balance 779,880 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F11: Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.480 to $109.470. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 14 · 2026-10-08 · Sale · Disposed 11,900 · Balance 767,980 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F12: Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.510 to $110.500. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 15 · 2026-10-08 · Sale · Disposed 200 · Balance 767,780 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $18.41 · Expires 2028-02-14 | Direct | 61,552 |
Reported balance
After 2026-10-06 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-10-06 · Exercise / conversion · Disposed 20,000 · Balance 61,552 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F13: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $18.41 · Expires 2028-02-14 | Direct | 41,552 |
Reported balance
After 2026-10-07 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-10-07 · Exercise / conversion · Disposed 20,000 · Balance 41,552 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F13: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $18.41 · Expires 2028-02-14 | Direct | 21,552 |
Reported balance
After 2026-10-08 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2026-10-08 · Exercise / conversion · Disposed 20,000 · Balance 21,552 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F13: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028.
F2: Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.480 to $108.290. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.530 to $109.520. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4: Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.530 to $110.510. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5: Represents a weighted average sales price per share. The shares were sold at prices ranging from $110.530 to $111.210. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6: Represents a weighted average sales price per share. The shares were sold at prices ranging from $110.360 to $111.350. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F7: Represents a weighted average sales price per share. The shares were sold at prices ranging from $111.380 to $112.360. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F8: Represents a weighted average sales price per share. The shares were sold at prices ranging from $112.400 to $113.190. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F9: Represents a weighted average sales price per share. The shares were sold at prices ranging from $113.590 to $113.860. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F10: Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.480 to $108.475. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F11: Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.480 to $109.470. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F12: Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.510 to $110.500. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F13: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018.
QUEST DIAGNOSTICS INC
Report date May 25, 2021 · Filed May 25, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,260 |
Reported balance
After 2021-05-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-05-25 · Grant · Acquired 1,363 · Balance 6,260 F1: Represents an award of restricted share units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted share units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2025 Filed Aug 13, 2025 22:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 20,000 | $8.11 Strike: $8.11 | $162,200.00 |
DisclosureSEC source: 0001415889-25-021681 · form4-08132025_100858.xml · derivative · entry 11 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 216,569 Underlying: Common Stock · 20,000 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026. F8 · derivative.exercise_date: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 3, 2016. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 22:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 6,958 | $64.00 | $445,318.96 |
DisclosureSEC source: 0001415889-25-021681 · form4-08132025_100858.xml · nonDerivative · entry 6 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 733,719 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026. F5 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $63.745 to $64.24. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 22:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 13,042 | $63.24 | $824,802.16 |
DisclosureSEC source: 0001415889-25-021681 · form4-08132025_100858.xml · nonDerivative · entry 5 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 740,677 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026. F4 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $62.68 to $63.67. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 22:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 20,000 | $8.11 | $162,200.00 |
DisclosureSEC source: 0001415889-25-021681 · form4-08132025_100858.xml · nonDerivative · entry 4 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 753,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 22:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 20,000 | $8.11 Strike: $8.11 | $162,200.00 |
DisclosureSEC source: 0001415889-25-021681 · form4-08132025_100858.xml · derivative · entry 10 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 236,569 Underlying: Common Stock · 20,000 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026. F8 · derivative.exercise_date: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 3, 2016. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 22:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 1,283 | $63.60 | $81,596.23 |
DisclosureSEC source: 0001415889-25-021681 · form4-08132025_100858.xml · nonDerivative · entry 3 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 733,719 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026. F3 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $63.54 to $63.63. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 22:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 18,717 | $63.01 | $1,179,320.74 |
DisclosureSEC source: 0001415889-25-021681 · form4-08132025_100858.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 735,002 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026. F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $62.54 to $63.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 22:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 20,000 | $8.11 | $162,200.00 |
DisclosureSEC source: 0001415889-25-021681 · form4-08132025_100858.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 753,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026. Read SEC document |
| July 10, 2025 Filed Jul 10, 2025 23:43 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 20,000 | $8.11 Strike: $8.11 | $162,200.00 |
DisclosureSEC source: 0001415889-25-019653 · form4-07102025_110726.xml · derivative · entry 12 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 256,569 Underlying: Common Stock · 20,000 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026. F8 · derivative.exercise_date: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 3, 2016. Read SEC document |
| July 10, 2025 Filed Jul 10, 2025 23:43 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 15,746 | $57.62 | $907,237.28 |
DisclosureSEC source: 0001415889-25-019653 · form4-07102025_110726.xml · nonDerivative · entry 9 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 733,719 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026. F7 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $57.185 to $57.94. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 10, 2025 Filed Jul 10, 2025 23:43 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 4,254 | $56.74 | $241,380.47 |
DisclosureSEC source: 0001415889-25-019653 · form4-07102025_110726.xml · nonDerivative · entry 8 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 749,465 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026. F6 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $56.184 to $57.17. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 10, 2025 Filed Jul 10, 2025 23:43 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 20,000 | $8.11 | $162,200.00 |
DisclosureSEC source: 0001415889-25-019653 · form4-07102025_110726.xml · nonDerivative · entry 7 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 753,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026. Read SEC document |
| July 09, 2025 Filed Jul 10, 2025 23:43 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 20,000 | $8.11 Strike: $8.11 | $162,200.00 |
DisclosureSEC source: 0001415889-25-019653 · form4-07102025_110726.xml · derivative · entry 11 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 276,569 Underlying: Common Stock · 20,000 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026. F8 · derivative.exercise_date: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 3, 2016. Read SEC document |
| July 09, 2025 Filed Jul 10, 2025 23:43 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 208 | $57.08 | $11,871.81 |
DisclosureSEC source: 0001415889-25-019653 · form4-07102025_110726.xml · nonDerivative · entry 6 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 733,719 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026. F5 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $57.05 to $57.10. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 09, 2025 Filed Jul 10, 2025 23:43 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 19,792 | $56.43 | $1,116,783.39 |
DisclosureSEC source: 0001415889-25-019653 · form4-07102025_110726.xml · nonDerivative · entry 5 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 733,927 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026. F4 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $56.055 to $57.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 09, 2025 Filed Jul 10, 2025 23:43 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 20,000 | $8.11 | $162,200.00 |
DisclosureSEC source: 0001415889-25-019653 · form4-07102025_110726.xml · nonDerivative · entry 4 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 753,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026. Read SEC document |
| July 08, 2025 Filed Jul 10, 2025 23:43 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 20,000 | $8.11 Strike: $8.11 | $162,200.00 |
DisclosureSEC source: 0001415889-25-019653 · form4-07102025_110726.xml · derivative · entry 10 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 296,569 Underlying: Common Stock · 20,000 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026. F8 · derivative.exercise_date: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 3, 2016. Read SEC document |
| July 08, 2025 Filed Jul 10, 2025 23:43 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 16,402 | $55.74 | $914,214.68 |
DisclosureSEC source: 0001415889-25-019653 · form4-07102025_110726.xml · nonDerivative · entry 3 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 733,719 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026. F3 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $55.17 to $56.16. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 08, 2025 Filed Jul 10, 2025 23:43 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 3,598 | $54.48 | $196,029.83 |
DisclosureSEC source: 0001415889-25-019653 · form4-07102025_110726.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 750,121 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026. F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $54.17 to $55.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 08, 2025 Filed Jul 10, 2025 23:43 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 20,000 | $8.11 | $162,200.00 |
DisclosureSEC source: 0001415889-25-019653 · form4-07102025_110726.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 753,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026. Read SEC document |
| June 24, 2025 Filed Jun 24, 2025 21:40 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 20,000 | $8.11 Strike: $8.11 | $162,200.00 |
DisclosureSEC source: 0001415889-25-018118 · form4-06242025_090608.xml · derivative · entry 10 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 316,569 Underlying: Common Stock · 20,000 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. F6 · derivative.exercise_date: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 3, 2016. Read SEC document |
| June 24, 2025 Filed Jun 24, 2025 21:40 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 15,511 | $53.91 | $836,213.52 |
DisclosureSEC source: 0001415889-25-018118 · form4-06242025_090608.xml · nonDerivative · entry 7 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 733,719 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. F5 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $53.65 to $54.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 24, 2025 Filed Jun 24, 2025 21:40 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 4,489 | $53.11 | $238,406.30 |
DisclosureSEC source: 0001415889-25-018118 · form4-06242025_090608.xml · nonDerivative · entry 6 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 749,230 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. F4 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $52.64 to $53.63. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 24, 2025 Filed Jun 24, 2025 21:40 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 20,000 | $8.11 | $162,200.00 |
DisclosureSEC source: 0001415889-25-018118 · form4-06242025_090608.xml · nonDerivative · entry 5 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 753,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. Read SEC document |
| June 23, 2025 Filed Jun 24, 2025 21:40 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 20,000 | $8.11 Strike: $8.11 | $162,200.00 |
DisclosureSEC source: 0001415889-25-018118 · form4-06242025_090608.xml · derivative · entry 9 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 336,569 Underlying: Common Stock · 20,000 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. F6 · derivative.exercise_date: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 3, 2016. Read SEC document |
| June 23, 2025 Filed Jun 24, 2025 21:40 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 20,000 | $52.57 | $1,051,460.00 |
DisclosureSEC source: 0001415889-25-018118 · form4-06242025_090608.xml · nonDerivative · entry 4 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 733,719 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. F3 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $51.94 to $52.87. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 23, 2025 Filed Jun 24, 2025 21:40 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 20,000 | $8.11 | $162,200.00 |
DisclosureSEC source: 0001415889-25-018118 · form4-06242025_090608.xml · nonDerivative · entry 3 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 753,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 21:40 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 20,000 | $8.11 Strike: $8.11 | $162,200.00 |
DisclosureSEC source: 0001415889-25-018118 · form4-06242025_090608.xml · derivative · entry 8 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 356,569 Underlying: Common Stock · 20,000 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. F6 · derivative.exercise_date: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 3, 2016. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 21:40 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 20,000 | $52.96 | $1,059,200.00 |
DisclosureSEC source: 0001415889-25-018118 · form4-06242025_090608.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 733,719 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $52.71 to $53.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 21:40 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 20,000 | $8.11 | $162,200.00 |
DisclosureSEC source: 0001415889-25-018118 · form4-06242025_090608.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 753,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. Read SEC document |
| February 23, 2025 Filed Feb 24, 2025 22:01 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 22,436 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005294 · form4-02242025_100237.xml · derivative · entry 3 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,308 Underlying: Common Stock · 22,436 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 23, 2025 Filed Feb 24, 2025 22:01 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 12,081 | $57.75 | $697,677.75 |
DisclosureSEC source: 0001415889-25-005294 · form4-02242025_100237.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 733,719 F1 · shares: The reported disposition of 12,081 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 23, 2025 Filed Feb 24, 2025 22:01 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 22,436 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005294 · form4-02242025_100237.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 745,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 23:47 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 67,027 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005171 · form4-02212025_110222.xml · derivative · entry 2 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,027 Underlying: Common Stock · 67,027 shares Expires not disclosed F2 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. F2 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 23:47 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 71,038 | $0.00 Strike: $57.44 | $0.00 |
DisclosureSEC source: 0001415889-25-005171 · form4-02212025_110222.xml · derivative · entry 1 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,038 Underlying: Common Stock · 71,038 shares Expires 2035-02-20 F1 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:37 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 16,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004506 · form4-02182025_110248.xml · derivative · entry 12 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,749 Underlying: Common Stock · 16,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F5 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:37 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 21,009 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004506 · form4-02182025_110248.xml · derivative · entry 11 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,009 Underlying: Common Stock · 21,009 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F5 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:37 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionPerformance Stock Units · Derivative | 71,810 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004506 · form4-02182025_110248.xml · derivative · entry 10 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 71,810 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer. F6 · derivative.expiration_date: This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:37 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 9,087 | $58.29 | $529,681.23 |
DisclosureSEC source: 0001415889-25-004506 · form4-02182025_110248.xml · nonDerivative · entry 8 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 723,364 F4 · shares: The reported disposition of 9,087 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:37 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 16,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004506 · form4-02182025_110248.xml · nonDerivative · entry 7 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 732,451 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:37 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 11,313 | $58.29 | $659,434.77 |
DisclosureSEC source: 0001415889-25-004506 · form4-02182025_110248.xml · nonDerivative · entry 6 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 715,576 F3 · shares: The reported disposition of 11,313 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:37 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 21,009 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004506 · form4-02182025_110248.xml · nonDerivative · entry 5 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 726,889 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:37 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 38,668 | $58.29 | $2,253,957.72 |
DisclosureSEC source: 0001415889-25-004506 · form4-02182025_110248.xml · nonDerivative · entry 4 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 705,880 F2 · shares: The reported disposition of 38,668 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:37 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 71,810 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004506 · form4-02182025_110248.xml · nonDerivative · entry 3 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 744,548 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2025 Filed Feb 18, 2025 23:37 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 13,092 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004506 · form4-02182025_110248.xml · derivative · entry 9 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,092 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F5 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 15, 2025 Filed Feb 18, 2025 23:37 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 7,098 | $58.29 | $413,742.42 |
DisclosureSEC source: 0001415889-25-004506 · form4-02182025_110248.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 672,738 F1 · shares: The reported disposition of 7,098 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 15, 2025 Filed Feb 18, 2025 23:37 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 13,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004506 · form4-02182025_110248.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 679,836 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:08 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantPerformance Stock Units · Derivative | 96,155 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004234 · form4-02142025_110239.xml · derivative · entry 4 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,155 Underlying: Common Stock · 96,155 shares Expires not disclosed F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:08 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantPerformance Stock Unit · Derivative | 23,260 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004234 · form4-02142025_110239.xml · derivative · entry 3 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,260 Underlying: Common Stock · 23,260 shares Expires not disclosed F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:08 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantPerformance Stock Units · Derivative | 20,008 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004234 · form4-02142025_110239.xml · derivative · entry 2 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,364 Underlying: Common Stock · 20,008 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2023 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2023 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.